Literature DB >> 15857930

Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

Raghavan Raju1, Marinos C Dalakas.   

Abstract

To explore the biological significance of gene expression in the pathogenesis of inflammatory myopathies, we performed microarray experiments followed by real-time PCR and immunohistochemistry on muscle biopsies obtained before and after therapy from patients with dermatomyositis (DM) who improved and patients with inclusion body myositis (sIBM) who did not improve after controlled trials with three monthly intravenous immunoglobulin (IVIg) infusions. The pretreatment biopsies showed high expression of immunoglobulin, adhesion molecules, chemokines and cytokine genes in both sIBM and DM (sIBM > DM). In the repeated biopsies of DM patients who clinically improved, 2206 genes were downregulated more than 1.5-fold; in contrast, 1700 of the same genes remained unchanged in sIBM patients who did not improve. Genes markedly downregulated in DM, but not sIBM, were interleukin 22, Kallmann syndrome 1 (KAL-1), an adhesion molecule shown for the first time in muscle, ICAM-1, complement C1q, and several structural protein genes. Because mRNA for KAL-1 was selectively upregulated in vitro by transforming growth factor (TGF) beta1, a fibrogenic cytokine immunolocalized in the endomysial connective tissue of pretreatment DM muscles, the downregulation of both TGF-beta and KAL-1 after IVIg only in DM suggests that these molecules have a functional role in connective tissue proliferation and fibrosis. The improved muscles of DM, but not sIBM, showed upregulation of chemokines CXCL9 (Mig) and CXCL11, and several immunoglobulin-related genes, suggesting an effect on muscle remodelling and regeneration. The results suggest that IVIg modulates several immunoregulatory or structural muscle genes, but only a subset of them associated with inflammatory mediators, fibrosis and muscle remodelling are connected with the clinical response. Gene arrays, when combined with clinical assessments, may provide important information in the pathogenesis of inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857930     DOI: 10.1093/brain/awh518

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  34 in total

1.  Circulatory Levels of C-X-C Motif Chemokine Ligands 1, 9, and 10 Are Elevated in Patients with Ischemic Stroke.

Authors:  Masoud Amin; Alireza Vakilian; Mohammad Hossein Mahmoodi; Gholamhossein Hassanshahi; Soudeh Khanamani Falahati-Pour; Maryam Rafiei Dolatabadi; Ali Esmaeili Nadimi
Journal:  Eurasian J Med       Date:  2017-06

2.  Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: effects on clinicopathological features and immunoregulatory genes.

Authors:  Marinos C Dalakas
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 3.  Role of IVIg in autoimmune, neuroinflammatory and neurodegenerative disorders of the central nervous system: present and future prospects.

Authors:  Marinos C Dalakas
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

4.  An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity.

Authors:  Emily C Baechler; Jason W Bauer; Catherine A Slattery; Ward A Ortmann; Karl J Espe; Jill Novitzke; Steven R Ytterberg; Peter K Gregersen; Timothy W Behrens; Ann M Reed
Journal:  Mol Med       Date:  2007 Jan-Feb       Impact factor: 6.354

Review 5.  Advances in the immunobiology and treatment of inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Curr Rheumatol Rep       Date:  2007-08       Impact factor: 4.592

Review 6.  Advances in the understanding of the mechanism of action of IVIg.

Authors:  Hans-Peter Hartung
Journal:  J Neurol       Date:  2008-07       Impact factor: 4.849

7.  The inflammatory milieu in idiopathic inflammatory myositis.

Authors:  Ann M Reed; Floranne Ernste
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 8.  Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Authors:  Jan D Lünemann; Falk Nimmerjahn; Marinos C Dalakas
Journal:  Nat Rev Neurol       Date:  2015-01-06       Impact factor: 42.937

Review 9.  Clinical applications of intravenous immunoglobulins in neurology.

Authors:  R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

10.  Transforming growth factor-β regulates the expression of anosmin (KAL-1) in human retinal pigment epithelial cells.

Authors:  Raghavan Raju; Bixi Jian; John J Hooks; Chandrasekharam N Nagineni
Journal:  Cytokine       Date:  2013-01-26       Impact factor: 3.861

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.